Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00699998 · ClinicalTrials.gov registry record · Phase 3

A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects

A Phase 3 study, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 3
Development phase
9,326
Enrollment target

NCT00699998: Completed Phase 3 study, sponsored by Eli Lilly and Company.

NCT00699998 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 9,326 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1110% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00699998, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 3
Development phase
9,326 participants
Enrollment target

Study Summary

This study will evaluate the relative efficacy and safety of prasugrel and clopidogrel in a medically managed Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) acute coronary syndrome (ACS) population (that is, patients who are not managed with acute coronary revascularization).

Primary Outcome

The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee.

Interventions

  • DRUG Clopidogrel
  • DRUG Prasugrel
  • DRUG Commercially-available Aspirin

Trial Details

FieldValue
Enrollment Target 9,326 participants
Start Date 2008-06
Est. Completion 2012-04
Phase Phase 3
Eli Lilly and Company

1,341 total trials

What the finished NCT00699998 record still lists

NCT00699998 is an interventional study that assigns participants to a tested intervention. Its 9,326 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1110% higher).

The record links to 0 conditions, and to 3 interventions - of which Clopidogrel is the first listed.

NCT00699998 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00699998 about?

NCT00699998 is a clinical study titled "A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects". This study will evaluate the relative efficacy and safety of prasugrel and clopidogrel in a medically managed Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) acute coronary syndrome (ACS) population (that is, patients who are not managed with acute coronary revascularization).

What is the current status of trial NCT00699998?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 9,326 participants. The study started on 2008-06. Estimated completion is 2012-04.

What interventions are being tested in trial NCT00699998?

The interventions under investigation include: Clopidogrel (DRUG), Prasugrel (DRUG), Commercially-available Aspirin (DRUG).

Who is sponsoring clinical trial NCT00699998?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00699998's enrollment target sits among peer trials

9,326 31st of 2000 higher than 1,970 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06284408 · 9,460 participants · NA

    Centralized Screening Unit (CSU) at Montefiore-Einstein

  • NCT05080673 · 9,500 participants · NA

    Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

  • NCT06946355 · 9,119 participants · NA

    Food-based Support for Hospitalized Children and Their Families

  • NCT02000089 · 9,000 participants · Phase 3

    The Cancer of the Pancreas Screening-5 CAPS5)Study

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00699998, the US trial registry maintained by the National Library of Medicine. NCT00699998 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.